.Merck & Co.'s TIGIT program has gone through another setback. Months after shuttering a period 3...
.After a year defined through pipeline cuts, the shift of its own chief executive officer as well as...
.Cullinan Therapeutics was blown away sufficient with Port BioMed's bispecific immune reactor that i...
.In this particular week's episode of "The Top Pipe," we're diving into Tough Biotech's annual Fierc...
.The confetti is still flying coming from Eli Lilly's gathering commemorating the approval of Alzhei...
.Accept to recently's Chutes & Ladders, our summary of substantial management hirings, shootings ...
.Complying with a poor revealing for Lykos Therapeutics' MDMA candidate for trauma at a recent FDA a...
.AN2 Therapies is actually reconsidering its own business in feedback to lackluster midphase records...
.Merck & Co. is paying $700 million ahead of time to test Amgen in a blood stream cancer cells ma...
.With Gilead Sciences about to an FDA decision for its liver illness medication seladelpar, the firm...